1,307
Participants
Start Date
November 30, 2020
Primary Completion Date
September 13, 2022
Study Completion Date
September 13, 2022
INO-4800
INO-4800 was administered ID on Day 0 and Day 28.
CELLECTRA® 2000
EP using the CELLECTRA® 2000 device was administered following ID delivery of INO-4800 on Day 0 and Day 28.
Placebo
Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID on Day 0 and Day 28.
CELLECTRA® 2000
EP using the CELLECTRA® 2000 device was administered following ID delivery of sterile saline sodium citrate (SSC) buffer (SSC-0001) on Day 0 and Day 28.
University of Pennsylvania, Philadelphia
Thomas Jefferson University, Philadelphia
Walter Reed Army Institute of Research, Silver Spring
AMR South Florida, Coral Gables
Clinical Research Trials of Florida, Inc, Tampa
AMR Lexington, Lexington
BRCR Global Mexico, Guadalajara
Ascension St. John Hospital, Detroit
AMR Kansas City, Kansas City
Eukarya Pharmasite SC, Monterrey
SMIQ, S. de R. L. de C.V., Querétaro
Unidad de Medicina Especializada SMA, San Juan del Río
Tekton Research, San Antonio
DM Clinical Research, Tomball
Clinica de la Costa LTDA, Barranquilla
Corazon IPS S.A.S, Barranquilla
Ips Centro Cientifico Asistencial Sas, Barranquilla
Advanced Clinical Research, West Jordan
Central Phoenix Synexus Clinical Research, Phoenix
Synexus Clinical Research US, Inc - Phoenix Southeast, Chandler
AMR Tempe, Tempe
AMR, Clinical Research Consortium- Las Vegas, Las Vegas
FAICIC S. de R.L. de C.V., Veracruz
Optimal Research, LLC, San Diego
Centro de Investigaciones Clinicas IPS Cardiomet Pereira, Pereira
Centro de Investigacion Medico Asistencial S.A.S, Barranquilla
Clinstile, SA de CV, Mexico City
Lead Sponsor
Advaccine (Suzhou) Biopharmaceuticals Co., Ltd.
INDUSTRY
Inovio Pharmaceuticals
INDUSTRY